The	O
interleukin-8	B-DNA
AP-1	I-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	B-DNA
promoters	I-DNA
,	O
the	O
AP-1	B-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	B-DNA
or	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	B-DNA
site	I-DNA
of	O
PMA/ionomycin-induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti-JunD	B-protein
or	O
c-Fos	B-protein
antibody	I-protein
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B-protein
B-like	I-protein
site	I-protein
binding	I-protein
complexes	I-protein
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B-protein
against	O
the	O
human	B-protein
Rel	I-protein
family	I-protein
proteins	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
,	O
p50	B-protein
,	O
and	O
p49	B-protein
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA/ionomycin-induced	O
activation	O
through	O
authentic	O
kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
gene	I-DNA
,	O
to	O
which	O
NF-kappa	B-protein
B	I-protein
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B-protein
factors	I-protein
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	B-DNA
NF-AT	I-DNA
and	I-DNA
NFIL-2A	I-DNA
sites	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
but	O
also	O
the	O
IL-8	B-protein
AP-1	B-DNA
and	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Tez	NULL
Journat	NULL
or	NULL
Vol	NULL
.	NULL

269	NULL
,	NULL
No	NULL
.	NULL

11	NULL
,	NULL
Issue	NULL
of	NULL
March	NULL
18	NULL
,	NULL
pp	NULL
.	NULL

8582-8589	NULL
,	NULL
1994	NULL
Printed	NULL
in	NULL
U.S.A	NULL
.	NULL

The	NULL
Interleukin-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
Sites	NULL
Are	NULL
Genetic	NULL
End	NULL
Targets	NULL
of	NULL
FK506-sensitive	NULL
Pathway	NULL
Accompanied	NULL
by	NULL
Calcium	NULL
Mobilization*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
September	NULL
183	NULL
,	NULL
1993	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
November	NULL
15	NULL
,	NULL
1993	NULL
)	NULL
Shu-ichi	NULL
Okamoto	NULL
?	NULL

,	NULL
Naofumi	NULL
Mukaidat	NULL
,	NULL
Kazuo	NULL
Yasumoto	NULL
?	NULL

#	NULL
§	NULL
,	NULL
Nancy	NULL
Ricey	NULL
,	NULL
Yuji	NULL
Ishikawat	NULL
,	NULL
Hyogo	NULL
Horiguchit	NULL
,	NULL
Seishi	NULL
Murakami	NULL
,	NULL
and	NULL
Kouji	NULL
Matsushimat**	NULL
From	NULL
the	NULL
Departments	NULL
of	NULL
{	NULL
Pharmacology	NULL
,	NULL
§Surgery	NULL
,	NULL
and	NULL
||Biophysics	NULL
,	NULL
Cancer	NULL
Research	NULL
Institute	NULL
,	NULL
Kanazawa	NULL
University	NULL
,	NULL
13-1	NULL
,	NULL
Takara-Machi	NULL
,	NULL
Kanazawa	NULL
920	NULL
,	NULL
Japan	NULL
and	NULL
the	NULL
Advanced	NULL
BioScience	NULL
Laboratories-Basic	NULL
Research	NULL
Program	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Frederick	NULL
Cancer	NULL
Research	NULL
and	NULL
Development	NULL
Center	NULL
,	NULL
Frederick	NULL
,	NULL
Maryland	NULL
21702-1201	NULL
FK506	NULL
,	NULL
an	NULL
immunosuppressant	NULL
,	NULL
inhibits	NULL
the	NULL
production	NULL
of	NULL
several	NULL
cytokines	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
FK506	NULL
suppressed	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
chemotactic	NULL
cytokine	NULL
,	NULL
interleukin-8	NULL
(	NULL
IL-8	NULL
)	NULL
in	NULL
a	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
cells	NULL
,	NULL
activated	NULL
by	NULL
phorbol	NULL
12-myristate	NULL
13-ac-etate	NULL
(	NULL
PMA	NULL
)	NULL
and	NULL
calcium	NULL
(	NULL
Ca**	NULL
)	NULL
ionophore	NULL
(	NULL
ionomycin	NULL
)	NULL
.	NULL

By	NULL
deleted	NULL
and	NULL
mutated	NULL
analysis	NULL
of	NULL
the	NULL
IL-8	NULL
promoters	NULL
,	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
were	NULL
identified	NULL
as	NULL
the	NULL
responsive	NULL
elements	NULL
for	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

FK506	NULL
suppressed	NULL
the	NULL
transcriptions	NULL
through	NULL
the	NULL
AP-1	NULL
or	NULL
«	NULL
B-like	NULL
sites	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
Ca**-mobilizing	NULL
agents	NULL
,	NULL
but	NULL
not	NULL
those	NULL
induced	NULL
by	NULL
Ca®*-independent	NULL
stimuli	NULL
.	NULL

In	NULL
gel	NULL
retardation	NULL
analysis	NULL
,	NULL
FK506	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
PMA/ionomycin-induced	NULL
nuclear	NULL
factors	NULL
,	NULL
which	NULL
were	NULL
recognized	NULL
with	NULL
anti-JunD	NULL
or	NULL
c-Fos	NULL
antibody	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
FK506	NULL
or	NULL
EGTA	NULL
(	NULL
Ca**	NULL
chelator	NULL
)	NULL
similarly	NULL
affected	NULL
the	NULL
formation	NULL
of	NULL
«	NULL
B-like	NULL
site	NULL
binding	NULL
complexes	NULL
,	NULL
which	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
any	NULL
antibodies	NULL
against	NULL
the	NULL
human	NULL
Rel	NULL
family	NULL
proteins	NULL
(	NULL
c-Rel	NULL
,	NULL
p65	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p49	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
previous	NULL
report	NULL
that	NULL
FK506	NULL
suppressed	NULL
the	NULL
PMA/ionomycin-induced	NULL
activation	NULL
through	NULL
authentic	NULL
«	NULL
B	NULL
site	NULL
of	NULL
immuno-globulin	NULL
(	NULL
Ig	NULL
)	NULL
gene	NULL
,	NULL
to	NULL
which	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
was	NULL
also	NULL
decreased	NULL
by	NULL
FK506	NULL
,	NULL
indicating	NULL
that	NULL
both	NULL
IL-8	NULL
xB-like	NULL
site	NULL
and	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
are	NULL
FK506-sensitive	NULL
in	NULL
spite	NULL
of	NULL
the	NULL
difference	NULL
of	NULL
binding	NULL
factors	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
not	NULL
only	NULL
the	NULL
reported	NULL
IL-2	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
and	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
,	NULL
but	NULL
also	NULL
the	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
are	NULL
terminals	NULL
of	NULL
FK506-sensitive	NULL
pathway	NULL
involving	NULL
Ca**	NULL
mobi-lization	NULL
.	NULL

Inflammation	NULL
is	NULL
accompanied	NULL
by	NULL
the	NULL
infiltration	NULL
of	NULL
specific	NULL
types	NULL
of	NULL
leukocytes	NULL
.	NULL

The	NULL
infiltration	NULL
of	NULL
leukocytes	NULL
is	NULL
mediated	NULL
by	NULL
chemoattractants	NULL
,	NULL
one	NULL
of	NULL
which	NULL
is	NULL
IL-8	NULL
.	NULL
``	NULL

IL-8	NULL
induces	NULL
che-motaxis	NULL
of	NULL
neutrophils	NULL
,	NULL
basophils	NULL
,	NULL
and	NULL
T	NULL
lymphocytes	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
IL-8	NULL
has	NULL
additional	NULL
functions	NULL
involved	NULL
in	NULL
inflammatory	NULL
processes	NULL
such	NULL
as	NULL
activation	NULL
of	NULL
neutrophils	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
,	NULL
up-regulation	NULL
of	NULL
adhesion	NULL
molecules	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
leukocytosis	NULL
(	NULL
4	NULL
)	NULL
.	NULL

These	NULL
features	NULL
of	NULL
IL-8	NULL
suggest	NULL
the	NULL
involvement	NULL
of	NULL
aberrant	NULL
IL-8	NULL
production	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
several	NULL
inflammatory	NULL
diseases	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

**	NULL
To	NULL
whom	NULL
all	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
81-762-62-8151	NULL
(	NULL
ext	NULL
.	NULL

5450	NULL
)	NULL
;	NULL
Fax	NULL
:	NULL
81-762-60-7704	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
AP-1	NULL
,	NULL
activator	NULL
pro-tein-1	NULL
;	NULL
C/EBP	NULL
,	NULL
CCAAT/enhancer-binding	NULL
protein	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myris-tate	NULL
acetate	NULL
;	NULL
ELISA	NULL
,	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
;	NULL
Ig	NULL
,	NULL
immu-noglobulin	NULL
;	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
.	NULL

Inflammatory	NULL
mediators	NULL
such	NULL
as	NULL
IL-1	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
and	NULL
lipopolysaccharide	NULL
,	NULL
strongly	NULL
induce	NULL
IL-8	NULL
production	NULL
in	NULL
a	NULL
broad	NULL
range	NULL
of	NULL
cells	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Our	NULL
previous	NULL
works	NULL
show	NULL
that	NULL
at	NULL
least	NULL
three	NULL
cis-elements	NULL
(	NULL
AP-1	NULL
,	NULL
C/EBP	NULL
-like	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
)	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
IL-8	NULL
gene	NULL
activation	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
relative	NULL
importance	NULL
of	NULL
three	NULL
elements	NULL
varies	NULL
in	NULL
a	NULL
cell	NULL
type-specific	NULL
manner	NULL
.	NULL

In	NULL
the	NULL
human	NULL
fibrosarcoma	NULL
cell	NULL
line	NULL
8387	NULL
,	NULL
the	NULL
C/EBP	NULL
-like	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
are	NULL
essential	NULL
,	NULL
but	NULL
the	NULL
AP-1	NULL
site	NULL
is	NULL
dispensable	NULL
(	NULL
5	NULL
,	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
the	NULL
human	NULL
gastric	NULL
cancer-derived	NULL
cell	NULL
line	NULL
MKN-45	NULL
,	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
are	NULL
im-portant	NULL
,	NULL
but	NULL
the	NULL
C/EBP	NULL
-like	NULL
site	NULL
is	NULL
not	NULL
necessary	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Several	NULL
suppressors	NULL
of	NULL
IL-8	NULL
production	NULL
have	NULL
been	NULL
reported	NULL
.	NULL

Cytokines	NULL
such	NULL
as	NULL
IL-4	NULL
(	NULL
8	NULL
)	NULL
,	NULL
IL-10	NULL
(	NULL
9	NULL
)	NULL
,	NULL
transforming	NULL
growth	NULL
fac-tor-B	NULL
,	NULL
interferon-B	NULL
,	NULL
and	NULL
interferon-y	NULL
(	NULL
1	NULL
,	NULL
2	NULL
,	NULL
10	NULL
)	NULL
counteract	NULL
the	NULL
induction	NULL
of	NULL
IL-8	NULL
production	NULL
by	NULL
IL-1	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
,	NULL
or	NULL
lipopolysaccharide	NULL
.	NULL

Immunomodulatory	NULL
drugs	NULL
such	NULL
as	NULL
gluco-corticoids	NULL
(	NULL
11	NULL
)	NULL
and	NULL
vitamin	NULL
D	NULL
;	NULL
(	NULL
12	NULL
)	NULL
also	NULL
act	NULL
as	NULL
suppressors	NULL
of	NULL
IL-8	NULL
production	NULL
.	NULL

An	NULL
immunosuppressive	NULL
drug	NULL
,	NULL
cyclosporin	NULL
A	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
suppress	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
IL-8	NULL
mRNA	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
(	NULL
13	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
IL-8	NULL
gene	NULL
suppression	NULL
by	NULL
any	NULL
of	NULL
these	NULL
substances	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
.	NULL

FK506	NULL
is	NULL
another	NULL
immunosuppressive	NULL
drug	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

14	NULL
)	NULL
.	NULL

At	NULL
an	NULL
early	NULL
step	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
both	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
inhibit	NULL
the	NULL
transcription	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
granulocyte	NULL
macrophage-colony	NULL
stimulating	NULL
factor	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
and	NULL
interferon-y	NULL
(	NULL
15-18	NULL
)	NULL
.	NULL

Several	NULL
independent	NULL
groups	NULL
have	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
on	NULL
the	NULL
nuclear	NULL
factors	NULL
controlling	NULL
the	NULL
IL-2	NULL
transcription	NULL
intensively	NULL
(	NULL
19-26	NULL
)	NULL
.	NULL

FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
suppressed	NULL
the	NULL
transcriptional	NULL
activity	NULL
through	NULL
the	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
by	NULL
inhibiting	NULL
the	NULL
Ca**/calmod-ulin-dependent	NULL
phosphatase	NULL
,	NULL
calcineurin	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
effects	NULL
on	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
sites	NULL
also	NULL
have	NULL
been	NULL
examined	NULL
.	NULL

Although	NULL
AP-1	NULL
sites	NULL
were	NULL
reported	NULL
to	NULL
be	NULL
resistant	NULL
to	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
(	NULL
19	NULL
,	NULL
20	NULL
,	NULL
23	NULL
,	NULL
24	NULL
,	NULL
26-28	NULL
)	NULL
,	NULL
the	NULL
effects	NULL
on	NULL
xB	NULL
sites	NULL
are	NULL
controversial	NULL
.	NULL

Some	NULL
groups	NULL
demonstrated	NULL
that	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
inhibited	NULL
the	NULL
Ca**-dependent	NULL
transcriptional	NULL
activity	NULL
on	NULL
«	NULL
B	NULL
sites	NULL
of	NULL
Ig	NULL
k	NULL
chain	NULL
gene	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
21	NULL
,	NULL
23	NULL
)	NULL
,	NULL
but	NULL
others	NULL
did	NULL
not	NULL
see	NULL
any	NULL
effects	NULL
on	NULL
«	NULL
B	NULL
site	NULL
of	NULL
IL-2	NULL
gene	NULL
(	NULL
14	NULL
,	NULL
20	NULL
,	NULL
24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
on	NULL
the	NULL
transcriptional	NULL
factors	NULL
regulating	NULL
the	NULL
expression	NULL
of	NULL
other	NULL
cytokine	NULL
genes	NULL
has	NULL
been	NULL
poorly	NULL
explored	NULL
.	NULL

The	NULL
inquiries	NULL
into	NULL
inhibition	NULL
of	NULL
IL-8	NULL
production	NULL
are	NULL
important	NULL
in	NULL
terms	NULL
of	NULL
anti-inflammation	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
report	NULL
that	NULL
FK506	NULL
suppressed	NULL
the	NULL
IL-8	NULL
transcription	NULL
in	NULL
a	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
,	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

We	NULL
identified	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
on	NULL
IL-8	NULL
gene	NULL
as	NULL
responsible	NULL
elements	NULL
for	NULL
PMA/ionomeyin-induced	NULL
activation	NULL
as	NULL
well	NULL
as	NULL
repression	NULL
by	NULL
FK506	NULL
treatment	NULL
.	NULL

Moreover	NULL
,	NULL
Ca*+-mobilizing	NULL
or	NULL
Ca*+*-inde-pendent	NULL
stimuli	NULL
were	NULL
used	NULL
to	NULL
elucidate	NULL
Ca**	NULL
dependence	NULL
of	NULL
8582	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
kB-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
FK506	NULL
action	NULL
on	NULL
the	NULL
responsive	NULL
elements	NULL
as	NULL
reported	NULL
on	NULL
the	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
of	NULL
IL-2	NULL
gene	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
FK506	NULL
on	NULL
the	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
responsive	NULL
elements	NULL
were	NULL
examined	NULL
by	NULL
gel	NULL
retardation	NULL
assay	NULL
.	NULL

Finally	NULL
,	NULL
since	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
was	NULL
not	NULL
observed	NULL
,	NULL
the	NULL
FK506	NULL
effect	NULL
on	NULL
the	NULL
activation	NULL
and	NULL
binding	NULL
factors	NULL
of	NULL
authentic	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
Ig	NULL
gene	NULL
was	NULL
examined	NULL
to	NULL
compare	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
with	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
in	NULL
FK506	NULL
action	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Culture-Jurkat	NULL
cells	NULL
,	NULL
human	NULL
T	NULL
cell	NULL
leukemia-derived	NULL
cells	NULL
,	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Nissui	NULL
Pharmaceutical	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
supplemented	NULL
with	NULL
5	NULL
%	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Flow	NULL
Laboratories	NULL
,	NULL
McLean	NULL
,	NULL
VA	NULL
)	NULL
,	NULL
penicillin	NULL
G	NULL
(	NULL
100	NULL
units/ml	NULL
,	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
streptomycin	NULL
(	NULL
100	NULL
ng/ml	NULL
,	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
glutamine	NULL
(	NULL
2	NULL
mm	NULL
,	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
in	NULL
a	NULL
humidified	NULL
incubator	NULL
containing	NULL
5	NULL
%	NULL
COz	NULL
in	NULL
air	NULL
.	NULL

Oligonucleotides-Oligonucleotides	NULL
were	NULL
synthesized	NULL
on	NULL
a	NULL
DNA	NULL
synthesizer	NULL
(	NULL
model	NULL
392	NULL
DNA/RNA	NULL
Synthesizer	NULL
,	NULL
Applied	NULL
Biosystems	NULL
,	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

These	NULL
oligonucleotides	NULL
were	NULL
used	NULL
as	NULL
primers	NULL
for	NULL
reverse	NULL
tran-scriptase-polymerase	NULL
chain	NULL
reaction	NULL
and	NULL
site-directed	NULL
mutagenesis	NULL
or	NULL
were	NULL
annealed	NULL
and	NULL
used	NULL
as	NULL
probes	NULL
after	NULL
end-labeling	NULL
with	NULL
|	NULL
«	NULL
-	NULL
``	NULL
``	NULL
P	NULL
]	NULL
dCTP	NULL
and	NULL
Klenow	NULL
polymerase	NULL
,	NULL
or	NULL
as	NULL
unlabeled	NULL
competitors	NULL
.	NULL

ELISA	NULL
for	NULL
Human	NULL
IL-8-The	NULL
concentration	NULL
of	NULL
IL-8	NULL
in	NULL
the	NULL
cell	NULL
culture	NULL
was	NULL
measured	NULL
by	NULL
ELISA	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
29	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
wells	NULL
on	NULL
96-well	NULL
microtiter	NULL
plate	NULL
(	NULL
Nune	NULL
,	NULL
Copenhagen	NULL
,	NULL
Denmark	NULL
)	NULL
were	NULL
coated	NULL
with	NULL
monoclonal	NULL
antibody	NULL
to	NULL
IL-8	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Polyclonal	NULL
rabbit	NULL
anti-IL-8	NULL
antibody	NULL
was	NULL
added	NULL
as	NULL
the	NULL
second	NULL
antibody	NULL
.	NULL

After	NULL
addition	NULL
of	NULL
alkaline	NULL
phosphatase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
antibody	NULL
(	NULL
Tago	NULL
,	NULL
Inc.	NULL
,	NULL
code	NULL
no	NULL
.	NULL

6500	NULL
,	NULL
Burlingame	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
the	NULL
plates	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

p-nitrophenyl	NULL
phosphate	NULL
(	NULL
1	NULL
mg/ml	NULL
,	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
and	NULL
allowed	NULL
to	NULL
react	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
1	NULL
m	NULL
NaOH	NULL
,	NULL
and	NULL
the	NULL
optical	NULL
density	NULL
at	NULL
405	NULL
nm	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
model	NULL
MPR-A4i	NULL
Micro	NULL
Plate	NULL
Reader	NULL
(	NULL
Tosoh	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

Antibodies	NULL
for	NULL
Human	NULL
Rel	NULL
Family	NULL
and	NULL
AP-1	NULL
Family-The	NULL
antibody	NULL
against	NULL
the	NULL
human	NULL
c-Rel	NULL
protein	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Rabbit	NULL
antisera	NULL
against	NULL
the	NULL
peptides	NULL
at	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
human	NULL
p65	NULL
(	NULL
DELFPLIFPAEPAQAS	NULL
)	NULL
,	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
human	NULL
p50	NULL
(	NULL
AFDDPYL-GRPEQMFH	NULL
)	NULL
,	NULL
or	NULL
the	NULL
N	NULL
terminus	NULL
of	NULL
human	NULL
p49	NULL
(	NULL
GESCYNPGLDGI-IEYDD	NULL
)	NULL
were	NULL
produced	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
polyclonal	NULL
IgG	NULL
against	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
JunD	NULL
,	NULL
and	NULL
c-Fos	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Plasmids-A	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
of	NULL
the	NULL
IL-8	NULL
promoter	NULL
was	NULL
generated	NULL
and	NULL
inserted	NULL
into	NULL
a	NULL
CAT	NULL
expression	NULL
vector	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
,	NULL
C/EBP	NULL
-like	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
in	NULL
-133	NULL
CAT	NULL
plasmid	NULL
,	NULL
was	NULL
carried	NULL
out	NULL
using	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
32	NULL
)	NULL
,	NULL
which	NULL
converted	NULL
the	NULL
AP-1	NULL
site	NULL
TGACTCA	NULL
(	NULL
-126	NULL
to	NULL
-120	NULL
bp	NULL
)	NULL
to	NULL
TATCTCA	NULL
,	NULL
the	NULL
C/EBP-like	NULL
site	NULL
CAGTTGCAAATCGT	NULL
(	NULL
-94	NULL
to	NULL
-81	NULL
bp	NULL
)	NULL
to	NULL
AGCTTGCAAATCGT	NULL
,	NULL
and	NULL
the	NULL
«	NULL
B-like	NULL
site	NULL
GGAATTTCCT	NULL
(	NULL
-80	NULL
to	NULL
-71	NULL
bp	NULL
)	NULL
to	NULL
TAACTTTCCT	NULL
.	NULL

These	NULL
constructs	NULL
were	NULL
designated	NULL
as	NULL
AP-1	NULL
site-mutated	NULL
,	NULL
C/EBP	NULL
-like	NULL
site-mutated	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
site-mutated	NULL
plas-mids	NULL
,	NULL
respectively	NULL
.	NULL

Two	NULL
copies	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
TGACTCA	NULL
)	NULL
,	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
GGAATTTCCT	NULL
}	NULL
,	NULL
or	NULL
two	NULL
copies	NULL
of	NULL
Ig	NULL
xB	NULL
site	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
were	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
IL-8	NULL
enhancerless	NULL
core	NULL
promoter	NULL
(	NULL
-50	NULL
bp	NULL
to	NULL
+44	NULL
bp	NULL
)	NULL
linked	NULL
to	NULL
firefly	NULL
luciferase	NULL
gene	NULL
.	NULL

All	NULL
plasmids	NULL
were	NULL
prepared	NULL
with	NULL
Qiagen	NULL
tip	NULL
500	NULL
(	NULL
Diagen	NULL
GmbH	NULL
,	NULL
Diissel-dorf	NULL
)	NULL
according	NULL
to	NULL
the	NULL
application	NULL
protocols	NULL
.	NULL

Cell	NULL
Transfection	NULL
and	NULL
CAT	NULL
and	NULL
Luciferase	NULL
Assays-Jurkat	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
108	NULL
cells	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
using	NULL
DEAE-dextran	NULL
(	NULL
500	NULL
ug	NULL
,	NULL
Pharmacia	NULL
LKB	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
as	NULL
described	NULL
(	NULL
33	NULL
)	NULL
.	NULL

After	NULL
24	NULL
h	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
,	NULL
Calbiochem	NULL
Behring	NULL
Corp.	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
TNF-a	NULL
(	NULL
100	NULL
units/ml	NULL
,	NULL
Dainippon	NULL
Pharmaceutical	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
forskolin	NULL
(	NULL
5	NULL
um	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
thapsigargin	NULL
(	NULL
500	NULL
nm	NULL
,	NULL
Sigma	NULL
)	NULL
were	NULL
added	NULL
to	NULL
different	NULL
cultures	NULL
.	NULL

After	NULL
additional	NULL
8	NULL
h	NULL
for	NULL
luciferase	NULL
assay	NULL
or	NULL
24	NULL
h	NULL
for	NULL
CAT	NULL
assay	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
amount	NULL
of	NULL
FK506	NULL
(	NULL
kind	NULL
gift	NULL
from	NULL
Fujisawa	NULL
Pharmaceutical	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
cell	NULL
lysate	NULL
was	NULL
prepared	NULL
.	NULL

Protein	NULL
concentrations	NULL
were	NULL
measured	NULL
by	NULL
the	NULL
method	NULL
of	NULL
Bradford	NULL
,	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
kit	NULL
with	NULL
bovine	NULL
serum	NULL
albumin	NULL
as	NULL
a	NULL
standard	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
determined	NULL
using	NULL
10	NULL
ug	NULL
of	NULL
each	NULL
sample	NULL
after	NULL
a	NULL
30-min	NULL
incubation	NULL
by	NULL
standard	NULL
methods	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Radioactivity	NULL
was	NULL
quantified	NULL
by	NULL
a	NULL
bicimaging	NULL
analyzer	NULL
(	NULL
BA	NULL
100	NULL
,	NULL
Fuji	NULL
Co.	NULL
,	NULL
Ltd.	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
.	NULL

For	NULL
luciferase	NULL
assay	NULL
system	NULL
,	NULL
PicaGene*	NULL
``	NULL
*	NULL
(	NULL
Toyo	NULL
Ink	NULL
Co.	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
was	NULL
used	NULL
.	NULL

The	NULL
light	NULL
intensity	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
Lumat	NULL
model	NULL
LB9501	NULL
lumino-meter	NULL
(	NULL
Berthold	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Results	NULL
were	NULL
confirmed	NULL
by	NULL
at	NULL
least	NULL
three	NULL
8583	NULL
60	NULL
-	NULL
#	NULL
-	NULL
PMA+ionomycin+FK506	NULL
O	NULL
__	NULL
no	NULL
treatment	NULL
50	NULL
40	NULL
30	NULL
IL-8	NULL
(	NULL
pg/ml	NULL
)	NULL
o	NULL
r	NULL
em	NULL
1	NULL
0	NULL
0.1	NULL
1	NULL
10	NULL
190	NULL
FKS06	NULL
(	NULL
nM	NULL
)	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

FK506	NULL
suppressed	NULL
the	NULL
IL-8	NULL
production	NULL
from	NULL
activated	NULL
Jurkat	NULL
cells	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
FK506	NULL
at	NULL
different	NULL
concentration	NULL
for	NULL
2	NULL
days	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
secreted	NULL
IL-8	NULL
in	NULL
the	NULL
culture	NULL
media	NULL
from	NULL
unstimulated	NULL
(	NULL
open	NULL
circles	NULL
)	NULL
or	NULL
activated	NULL
(	NULL
closed	NULL
circles	NULL
)	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
ELISA	NULL
.	NULL

independent	NULL
transfections	NULL
,	NULL
and	NULL
representative	NULL
data	NULL
are	NULL
shown	NULL
here	NULL
.	NULL

Nuclear	NULL
Extracts	NULL
and	NULL
Gel	NULL
Retardation	NULL
Assay-Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
for	NULL
1	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
,	NULL
or	NULL
EGTA	NULL
(	NULL
3	NULL
mm	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
35	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
20	NULL
pl	NULL
in	NULL
a	NULL
solution	NULL
consisting	NULL
of	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.9	NULL
,	NULL
60	NULL
mm	NULL
KCl	NULL
,	NULL
4	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mm	NULL
EDTA	NULL
,	NULL
1	NULL
mm	NULL
dithic-threitol	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
2	NULL
%	NULL
polyvinyl	NULL
alcohol	NULL
,	NULL
2	NULL
ug	NULL
poly	NULL
(	NULL
dl-dC	NULL
)	NULL
-poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Four	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
used	NULL
for	NULL
each	NULL
reaction	NULL
.	NULL

The	NULL
mixtures	NULL
with	NULL
or	NULL
without	NULL
either	NULL
competitors	NULL
or	NULL
antibodies	NULL
were	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
probe	NULL
(	NULL
3	NULL
x	NULL
10	NULL
``	NULL
cpm/reaction	NULL
)	NULL
.	NULL

After	NULL
another	NULL
20-min	NULL
incubation	NULL
at	NULL
25	NULL
°C	NULL
,	NULL
the	NULL
samples	NULL
were	NULL
electro-phoresed	NULL
in	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
acrylamide/N	NULL
,	NULL
N'-methylene	NULL
bis-acrylamide	NULL
,	NULL
30:1	NULL
)	NULL
with	NULL
0.25	NULL
x	NULL
Tris	NULL
borate	NULL
electrophoresis	NULL
buffer	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

RESULTS	NULL
IL-8	NULL
Production	NULL
by	NULL
Activated	NULL
Jurkat	NULL
Cells	NULL
Was	NULL
Inhibited	NULL
by	NULL
FK506-A	NULL
human	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA/ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
different	NULL
concentration	NULL
of	NULL
FK506	NULL
.	NULL

IL-8	NULL
was	NULL
not	NULL
detected	NULL
from	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
but	NULL
activated	NULL
Jurkat	NULL
cells	NULL
secreted	NULL
about	NULL
80	NULL
pg/ml	NULL
IL-8	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
}	NULL
.	NULL

FK506	NULL
inhibited	NULL
the	NULL
IL-8	NULL
production	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
with	NULL
IDs	NULL
,	NULL
=	NULL
0.25	NULL
nm	NULL
.	NULL

The	NULL
level	NULL
of	NULL
IL-8	NULL
mRNA	NULL
was	NULL
examined	NULL
with	NULL
reverse	NULL
tran-scriptase-polymerase	NULL
chain	NULL
reaction	NULL
.	NULL

The	NULL
IL-8	NULL
mRNA	NULL
was	NULL
detected	NULL
after	NULL
2	NULL
h	NULL
of	NULL
activation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
IL-8	NULL
mRNA	NULL
was	NULL
not	NULL
detected	NULL
from	NULL
activated	NULL
cells	NULL
with	NULL
FK506	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
FK506	NULL
reduced	NULL
the	NULL
amount	NULL
of	NULL
induced	NULL
IL-8	NULL
mRNA	NULL
.	NULL

Since	NULL
the	NULL
reduction	NULL
of	NULL
IL-8	NULL
mRNA	NULL
by	NULL
FK506	NULL
was	NULL
observed	NULL
at	NULL
early	NULL
phase	NULL
of	NULL
activation	NULL
,	NULL
within	NULL
2	NULL
h	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
primary	NULL
.	NULL

FK506	NULL
Suppressed	NULL
the	NULL
Activation	NULL
of	NULL
CAT	NULL
Gene	NULL
Linked	NULL
to	NULL
the	NULL
IL-8	NULL
Promoter-To	NULL
examine	NULL
whether	NULL
the	NULL
impairment	NULL
of	NULL
IL-8	NULL
mRNA	NULL
induction	NULL
by	NULL
FK506	NULL
was	NULL
due	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
transcription	NULL
,	NULL
the	NULL
5	NULL
'	NULL
region	NULL
(	NULL
from	NULL
+44	NULL
bp	NULL
up	NULL
to	NULL
-1481	NULL
bp	NULL
)	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
was	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
the	NULL
construct	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

FK506	NULL
inhibited	NULL
the	NULL
CAT	NULL
activity	NULL
induced	NULL
with	NULL
PMA/ionomycin	NULL
treatment	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
with	NULL
ID	NULL
;	NULL
,	NULL
=	NULL
0.4	NULL
ny	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
which	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
for	NULL
the	NULL
IL-8	NULL
secretion	NULL
(	NULL
0.25	NULL
nm	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
indicated	NULL
that	NULL
FK506	NULL
inhibited	NULL
the	NULL
IL-8	NULL
transcription	NULL
.	NULL

Both	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
Sites	NULL
Were	NULL
Necessary	NULL
for	NULL
the	NULL
IL-8	NULL
Gene	NULL
Activation	NULL
by	NULL
PMA	NULL
and	NULL
Ionomycin-Since	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
cis-elements	NULL
necessary	NULL
for	NULL
the	NULL
IL-8	NULL
gene	NULL
activation	NULL
differed	NULL
between	NULL
two	NULL
cell	NULL
types	NULL
(	NULL
5-7	NULL
)	NULL
,	NULL
the	NULL
cis-elements	NULL
responsible	NULL
for	NULL
IL-8	NULL
gene	NULL
activation	NULL
in	NULL
Jurkat	NULL
cells	NULL
were	NULL
identified	NULL
by	NULL
using	NULL
various	NULL
deletions	NULL
of	NULL
the	NULL
IL-8	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

PMA¥ionomycin	NULL
greatly	NULL
increased	NULL
the	NULL
CAT	NULL
activity	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
-1481	NULL
,	NULL
-272	NULL
,	NULL
and	NULL
-133	NULL
CAT	NULL
con-structs	NULL
,	NULL
and	NULL
slightly	NULL
increased	NULL
the	NULL
CAT	NULL
activity	NULL
in	NULL
cells	NULL
trans-	NULL
8584	NULL
-®-	NULL
_	NULL
PMA+ionomycin+FK506	NULL
©	NULL
__	NULL
no	NULL
treatment	NULL
CAT	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
t	NULL
r	NULL
0	NULL
0.1	NULL
1	NULL
10	NULL
``	NULL
100	NULL
FK506	NULL
(	NULL
nM	NULL
)	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

The	NULL
IL-8	NULL
promoter-driven	NULL
transcription	NULL
was	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

The	NULL
IL-8	NULL
promoter	NULL
(	NULL
-1481	NULL
bp	NULL
to	NULL
+	NULL
44	NULL
bp	NULL
)	NULL
,	NULL
linked	NULL
to	NULL
CAT	NULL
gene	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

After	NULL
a	NULL
24	NULL
h	NULL
incubation	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
FK506	NULL
at	NULL
various	NULL
concentrations	NULL
(	NULL
closed	NULL
circles	NULL
)	NULL
or	NULL
without	NULL
stimulant	NULL
(	NULL
open	NULL
circles	NULL
)	NULL
,	NULL
the	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

eo	NULL
O	NULL
no	NULL
treatment	NULL
H	NULL
PMA+ionomycin	NULL
B	NULL
PMA+ionomycin	NULL
+FK506	NULL
&	NULL
CAT	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
B	NULL
1481	NULL
-272	NULL
.	NULL

A33	NULL
94	NULL
«	NULL
85	NULL
-94	NULL
(	NULL
A7B-71	NULL
)	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Identification	NULL
of	NULL
the	NULL
responsive	NULL
elements	NULL
for	NULL
PMA	NULL
and	NULL
ionomycin-induced	NULL
transcription	NULL
.	NULL

Various	NULL
lengths	NULL
of	NULL
5	NULL
franking	NULL
region	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
,	NULL
linked	NULL
to	NULL
CAT	NULL
gene	NULL
,	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
Jurkat	NULL
cells	NULL
were	NULL
unstimulated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
{	NULL
shaded	NULL
bars	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
of	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
.	NULL

After	NULL
a	NULL
24	NULL
incubation	NULL
,	NULL
the	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

fected	NULL
with	NULL
-94	NULL
and	NULL
-85	NULL
CAT	NULL
constructs	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
FK506	NULL
reduced	NULL
all	NULL
CAT	NULL
activities	NULL
induced	NULL
by	NULL
PMA/ionomycin	NULL
transfected	NULL
with	NULL
these	NULL
plasmids	NULL
.	NULL

Maximum	NULL
CAT	NULL
expression	NULL
was	NULL
induced	NULL
with	NULL
the	NULL
-133	NULL
CAT	NULL
construct	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
minimally	NULL
essential	NULL
elements	NULL
for	NULL
the	NULL
IL-8	NULL
gene	NULL
regulation	NULL
are	NULL
present	NULL
within	NULL
the	NULL
3	NULL
'	NULL
region	NULL
downstream	NULL
of	NULL
-133	NULL
bp	NULL
.	NULL

There	NULL
are	NULL
three	NULL
known	NULL
cis-elements	NULL
,	NULL
AP-1	NULL
(	NULL
-126	NULL
bp	NULL
to	NULL
-120	NULL
bp	NULL
)	NULL
,	NULL
C/EBP	NULL
-like	NULL
(	NULL
-94	NULL
bp	NULL
to	NULL
-81	NULL
bp	NULL
)	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
(	NULL
-80	NULL
bp	NULL
to	NULL
-71	NULL
bp	NULL
)	NULL
sites	NULL
within	NULL
the	NULL
region	NULL
downstream	NULL
of	NULL
-133	NULL
bp	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
regulatory	NULL
role	NULL
of	NULL
the	NULL
AP-1	NULL
,	NULL
C/EBP	NULL
-like	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
was	NULL
further	NULL
studied	NULL
by	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
each	NULL
element	NULL
in	NULL
the	NULL
-133	NULL
CAT	NULL
plasmid	NULL
.	NULL

When	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
-133	NULL
(	NULL
wild	NULL
type	NULL
)	NULL
CAT	NULL
construct	NULL
,	NULL
PMA/ionomycin	NULL
induced	NULL
a	NULL
50-fold	NULL
increase	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
mutation	NULL
of	NULL
either	NULL
the	NULL
AP-1	NULL
site	NULL
or	NULL
the	NULL
«	NULL
B-like	NULL
site	NULL
severely	NULL
reduced	NULL
this	NULL
induction	NULL
of	NULL
the	NULL
CAT	NULL
activity	NULL
,	NULL
whereas	NULL
the	NULL
mutation	NULL
of	NULL
the	NULL
C/EBP	NULL
-like	NULL
site	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
inducibility	NULL
.	NULL

Collectively	NULL
,	NULL
two	NULL
elements	NULL
(	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
)	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
IL-8	NULL
gene	NULL
activation	NULL
in	NULL
Jurkat	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
PMA	NULL
and	NULL
ionomycin	NULL
stimulation	NULL
.	NULL

FK506	NULL
Suppressed	NULL
the	NULL
Transcriptional	NULL
Activation	NULL
through	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
Sites	NULL
Elicited	NULL
by	NULL
PMA	NULL
and	NULL
Ca*+*-mobilizing	NULL
Agents-To	NULL
examine	NULL
the	NULL
effects	NULL
of	NULL
FK506	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
through	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
,	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
(	NULL
TGACTCA	NULL
)	NULL
or	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
GGAATTTCCT	NULL
)	NULL
were	NULL
linked	NULL
to	NULL
the	NULL
enhanceriess	NULL
IL-8	NULL
core	NULL
promoter	NULL
(	NULL
-50	NULL
bp	NULL
to	NULL
+	NULL
44	NULL
bp	NULL
)	NULL
,	NULL
which	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
firefly	NULL
luciferase	NULL
gene	NULL
.	NULL

The	NULL
luciferase	NULL
gene	NULL
expression	NULL
driven	NULL
from	NULL
the	NULL
IL-8	NULL
core	NULL
promoter	NULL
was	NULL
not	NULL
induced	NULL
by	NULL
any	NULL
stimuli	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
,	NULL
PMA/ionomycin	NULL
stimulation	NULL
induced	NULL
the	NULL
AP-1	NULL
site-	NULL
or	NULL
IL-8	NULL
AP-1	NULL
and	NULL
kB-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
133	NULL
(	NULL
Wild	NULL
Type	NULL
)	NULL
CAT	NULL
-133	NULL
(	NULL
AP-1	NULL
site	NULL
mutated	NULL
)	NULL
CAT	NULL
+133	NULL
(	NULL
C/EBP-like	NULL
site	NULL
mutated	NULL
)	NULL
CAT	NULL
CJ	NULL
no	NULL
treatment	NULL
133	NULL
(	NULL
xB-like	NULL
N	NULL
PMA+ionomycin	NULL
site	NULL
mutated	NULL
)	NULL
CAT	NULL
T	NULL
T	NULL
T	NULL
v	NULL
T	NULL
u	NULL
1	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
CAT	NULL
activity	NULL
(	NULL
%	NULL
)	NULL
,	NULL
.	NULL

C/EBP	NULL
AP-1	NULL
binding	NULL
site	NULL
Iik/esile	NULL
xB	NULL
like	NULL
site	NULL
126__-120	NULL
94	NULL
_:81__-71	NULL
A	NULL
A	NULL
+1	NULL
-133	NULL
-94	NULL
0-85	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

The	NULL
relative	NULL
importance	NULL
of	NULL
the	NULL
AP-1	NULL
,	NULL
C/EBP-like	NULL
,	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
in	NULL
the	NULL
IL-8	NULL
promoter	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
(	NULL
-126	NULL
bp	NULL
to	NULL
-120	NULL
bp	NULL
;	NULL
TGACTCA	NULL
)	NULL
,	NULL
C/EBP-like	NULL
site	NULL
(	NULL
-94	NULL
bp	NULL
to	NULL
-81	NULL
bp	NULL
;	NULL
CAGTTGCAAATCGT	NULL
)	NULL
,	NULL
or	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
-80	NULL
bp	NULL
to	NULL
-71	NULL
bp	NULL
;	NULL
GGAATTTCCT	NULL
)	NULL
in	NULL
the	NULL
IL-8	NULL
promoter	NULL
(	NULL
-133	NULL
bp	NULL
to	NULL
+44	NULL
bp	NULL
)	NULL
,	NULL
linked	NULL
to	NULL
CAT	NULL
gene	NULL
,	NULL
were	NULL
mutated	NULL
to	NULL
TATCTCA	NULL
,	NULL
AGCTTGCAAATCGT	NULL
,	NULL
and	NULL
TAACTTTCCT	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
wild	NULL
type	NULL
and	NULL
mutated	NULL
plasmids	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
(	NULL
shaded	NULL
bars	NULL
)	NULL
.	NULL

After	NULL
a	NULL
24-h	NULL
incubation	NULL
,	NULL
the	NULL
CAT	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

«	NULL
B-like	NULL
site-driven	NULL
transcription	NULL
.	NULL

The	NULL
PMA/ionomycin-induced	NULL
transcription	NULL
through	NULL
the	NULL
AP-1	NULL
or	NULL
xB-like	NULL
sites	NULL
was	NULL
inhibited	NULL
by	NULL
Ca	NULL
?	NULL

*	NULL
chelator	NULL
,	NULL
EGTA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
Ca**	NULL
was	NULL
involved	NULL
in	NULL
the	NULL
PMA/ionomycin-induced	NULL
transcriptional	NULL
activation	NULL
of	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
.	NULL

FK506	NULL
reduced	NULL
the	NULL
PMA/	NULL
ionomycin-induced	NULL
transcriptions	NULL
through	NULL
both	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
FK506	NULL
decreased	NULL
the	NULL
AP-1	NULL
or	NULL
«	NULL
B-like	NULL
site-driven	NULL
transcription	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
thapsigargin	NULL
(	NULL
intracellular	NULL
Ca**	NULL
elevating	NULL
agent	NULL
by	NULL
inhibiting	NULL
Ca	NULL
``	NULL
+*-ATPase	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PMA	NULL
alone	NULL
also	NULL
increased	NULL
the	NULL
luciferase	NULL
gene	NULL
expression	NULL
driven	NULL
from	NULL
the	NULL
AP-1	NULL
or	NULL
«	NULL
B-like	NULL
sites	NULL
,	NULL
which	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Ca**-independent	NULL
stimuli	NULL
such	NULL
as	NULL
PMA	NULL
plus	NULL
forskolin	NULL
(	NULL
activator	NULL
of	NULL
adenyl	NULL
cyclase	NULL
)	NULL
,	NULL
PMA	NULL
plus	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
activated	NULL
the	NULL
transcription	NULL
through	NULL
the	NULL
AP-1	NULL
or	NULL
«	NULL
B-like	NULL
sites	NULL
,	NULL
which	NULL
were	NULL
not	NULL
significantly	NULL
inhibited	NULL
by	NULL
FK506	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
E	NULL
and	NULL
F	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
FK506	NULL
suppressed	NULL
the	NULL
activation	NULL
through	NULL
the	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
induced	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
Ca*+-mobilizing	NULL
agents	NULL
.	NULL

FK506	NULL
Did	NULL
Not	NULL
Have	NULL
Apparent	NULL
Effect	NULL
on	NULL
the	NULL
Complex	NULL
Formation	NULL
of	NULL
the	NULL
AP-1	NULL
Site	NULL
of	NULL
the	NULL
IL-8	NULL
Gene-In	NULL
gel	NULL
retardation	NULL
assays	NULL
,	NULL
the	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
responsive	NULL
elements	NULL
of	NULL
the	NULL
IL-8	NULL
promoter	NULL
were	NULL
examined	NULL
.	NULL

With	NULL
the	NULL
IL-8	NULL
-130/-116	NULL
probe	NULL
,	NULL
containing	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
TGACTCA	NULL
;	NULL
-126	NULL
bp	NULL
to	NULL
-120	NULL
bp	NULL
)	NULL
,	NULL
one	NULL
complex	NULL
was	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

FK506	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
this	NULL
induced	NULL
complex	NULL
formation	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
complex	NULL
formation	NULL
was	NULL
inhibited	NULL
by	NULL
AP-1	NULL
site	NULL
oligonucleotide	NULL
,	NULL
but	NULL
not	NULL
by	NULL
mutated	NULL
AP-1	NULL
site	NULL
oligonucleotide	NULL
(	NULL
TATCTCA	NULL
)	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
specificity	NULL
of	NULL
this	NULL
complex	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
constituents	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
complex	NULL
,	NULL
polyclonal	NULL
antibodies	NULL
against	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
JunD	NULL
,	NULL
or	NULL
c-Fos	NULL
were	NULL
added	NULL
to	NULL
the	NULL
gel	NULL
retardation	NULL
mixture	NULL
.	NULL

Anti-JunD	NULL
or	NULL
anti-c-Fos	NULL
antibody	NULL
supershifted	NULL
the	NULL
complexes	NULL
induced	NULL
by	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
of	NULL
FK506	NULL
,	NULL
whereas	NULL
other	NULL
antibodies	NULL
failed	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
7	NULL
,	NULL
and	NULL
8	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PMA/ionomycin	NULL
treatment	NULL
induced	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
binding	NULL
complex	NULL
including	NULL
JunD	NULL
and	NULL
c-Fos	NULL
,	NULL
which	NULL
was	NULL
not	NULL
altered	NULL
by	NULL
FK506	NULL
.	NULL

FK506	NULL
Affected	NULL
the	NULL
Complex	NULL
Formation	NULL
of	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
IL-8	NULL
AP-1	NULL
and	NULL
<	NULL
B-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
100090	NULL
7	NULL
control	NULL
FKS06	NULL
tonomycin	NULL
fonamycin+	NULL
FK806	NULL
PMA	NULL
PMA	NULL
FK506	NULL
fonomycin	NULL
«	NULL
FMA	NULL
fonomycint	NULL
PMA	NULL
+FK506	NULL
80000	NULL
60900	NULL
4A	NULL
@	NULL
D	NULL
a	NULL
u	NULL
o	NULL
0	NULL
a	NULL
a	NULL
40000	NULL
Lucifarase	NULL
Activity	NULL
(	NULL
R.	NULL
L	NULL
.	NULL

U	NULL
.	NULL
}	NULL

20000	NULL
X2	NULL
AP-1	NULL
ae	NULL
LUC	NULL
200000	NULL
7	NULL
E	NULL
control	NULL
[	NULL
J	NULL
PMA+Thapsigargin	NULL
IJ	NULL
PMA+Thapeigaigin+FK506	NULL
100080	NULL
4	NULL
Lucifarase	NULL
Activity	NULL
(	NULL
ALL	NULL
.	NULL
)	NULL

X2	NULL
AP-	NULL
ate	NULL
LUC	NULL
300000	NULL
W	NULL
contral	NULL
PMA+	NULL
Forskolin	NULL
PMA	NULL
»	NULL
Forekoiin+	NULL
FK506	NULL
PMA+	NULL
TNF	NULL
PMA+	NULL
TNF+	NULL
a	NULL
G	NULL
LJ	NULL
a	NULL
G	NULL
200000	NULL
4	NULL
100000	NULL
4	NULL
Luciferase	NULL
Activity	NULL
(	NULL
R.	NULL
L	NULL
.	NULL

U	NULL
.	NULL
)	NULL

0	NULL
X2	NULL
AP-1	NULL
site	NULL
LUC	NULL
8000	NULL
1	NULL
3.	NULL
control	NULL
IB	NULL
rxsos	NULL
I8	NULL
|	NULL
lonomycin	NULL
(	NULL
Q	NULL
lonomycin+	NULL
FK506	NULL
g	NULL
4	NULL
_L	NULL
sao	NULL
:	NULL
g	NULL
rua	NULL
3	NULL
©	NULL
FK506	NULL
a	NULL
C	NULL
fonomycin+	NULL
PMA	NULL
E	NULL
``	NULL
BB	NULL
lonomycin	NULL
:	NULL
PMA+	NULL
FKSC6	NULL
£	NULL
4009	NULL
7	NULL
<	NULL
%	NULL
8	NULL
$	NULL
-	NULL
2000	NULL
4	NULL
o	NULL
-	NULL
ey	NULL
/	NULL
-an	NULL
X3	NULL
IL-3	NULL
kB-the	NULL
ote	NULL
LUC	NULL
20008	NULL
7	NULL
E	NULL
contro	NULL
!	NULL

CJ	NULL
PMA+Thapsigargin	NULL
[	NULL
J|	NULL
PMA+	NULL
Thapeigargin+FK506	NULL
3	NULL
fel	NULL
&	NULL
z	NULL
E	NULL
10000	NULL
4	NULL
<	NULL
P	NULL
H	NULL
€	NULL
3	NULL
E	NULL
a	NULL
X3	NULL
1L-8	NULL
kB-like	NULL
site	NULL
LUC	NULL
8906	NULL
W	NULL
WR	NULL
control	NULL
C.	NULL
PMA+	NULL
Forskolin	NULL
EB	NULL
|	NULL
PMA+	NULL
Forskolin	NULL
»	NULL
FK306	NULL
[	NULL
g	NULL
|	NULL
PMA+	NULL
TNF	NULL
6000	NULL
7	NULL
EJ	NULL
PMA+	NULL
TNF+	NULL
FKSOG	NULL
5	NULL
_	NULL
€	NULL
&	NULL
H	NULL
+000	NULL
<	NULL
&	NULL
&	NULL
$	NULL
ind	NULL
2009	NULL
o	NULL
<	NULL
X3	NULL
IL-8	NULL
kB-iike	NULL
site	NULL
LUC	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Both	NULL
the	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
sites	NULL
were	NULL
FK506-sensitive	NULL
.	NULL

Two	NULL
copies	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
(	NULL
TGACTCA	NULL
)	NULL
(	NULL
4	NULL
,	NULL
C	NULL
,	NULL
and	NULL
E	NULL
)	NULL
or	NULL
three	NULL
copies	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
GGAATTTCCT	NULL
)	NULL
(	NULL
B	NULL
,	NULL
D	NULL
,	NULL
and	NULL
F	NULL
)	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
upstream	NULL
of	NULL
the	NULL
IL-8	NULL
enhancerless	NULL
promoter	NULL
(	NULL
-50	NULL
bp	NULL
to	NULL
+	NULL
44	NULL
bp	NULL
)	NULL
linked	NULL
to	NULL
luciferase	NULL
reporter	NULL
gene	NULL
,	NULL
which	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
combinations	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
for	NULL
8	NULL
h	NULL
before	NULL
the	NULL
luciferase	NULL
assays	NULL
.	NULL

C	NULL
and	NULL
D	NULL
,	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
thapsigargin	NULL
(	NULL
500	NULL
nu	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
.	NULL

E	NULL
and	NULL
F	NULL
,	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
combinations	NULL
of	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
forskolin	NULL
(	NULL
5	NULL
um	NULL
)	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
(	NULL
TNF-a	NULL
;	NULL
100	NULL
units/ml	NULL
)	NULL
,	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
.	NULL

R.L.U	NULL
.	NULL

,	NULL
relative	NULL
light	NULL
unit	NULL
.	NULL

Site-Incubation	NULL
of	NULL
radiolabeled	NULL
IL-8	NULL
-83/-69	NULL
oligomer	NULL
,	NULL
containing	NULL
the	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
GGAATTTCCT	NULL
;	NULL
-80	NULL
bp	NULL
to	NULL
-71	NULL
bp	NULL
)	NULL
,	NULL
with	NULL
Jurkat	NULL
nuclear	NULL
extracts	NULL
produced	NULL
three	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

From	NULL
unstimulated	NULL
cells	NULL
,	NULL
two	NULL
constitutive	NULL
complexes	NULL
were	NULL
de-tected	NULL
.	NULL

The	NULL
upper	NULL
faint	NULL
complex	NULL
was	NULL
designated	NULL
as	NULL
complex	NULL
A	NULL
and	NULL
the	NULL
lower	NULL
complex	NULL
as	NULL
complex	NULL
B	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

After	NULL
PMA/	NULL
ionomycin	NULL
treatment	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
complex	NULL
A	NULL
slightly	NULL
in-creased	NULL
,	NULL
but	NULL
the	NULL
level	NULL
of	NULL
complex	NULL
B	NULL
was	NULL
not	NULL
changed	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

From	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
plus	NULL
FK506	NULL
treated	NULL
cells	NULL
,	NULL
one	NULL
com	NULL
plex	NULL
,	NULL
complex	NULL
C	NULL
,	NULL
was	NULL
detected	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
mobility	NULL
of	NULL
complex	NULL
C	NULL
was	NULL
intermediate	NULL
between	NULL
those	NULL
of	NULL
complexes	NULL
A	NULL
and	NULL
B	NULL
,	NULL
which	NULL
was	NULL
more	NULL
clear	NULL
when	NULL
the	NULL
electrophoresis	NULL
was	NULL
performed	NULL
for	NULL
a	NULL
longer	NULL
time	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

These	NULL
complexes	NULL
were	NULL
not	NULL
formed	NULL
with	NULL
the	NULL
mutated	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
TAACTTTCCT	NULL
)	NULL
probe	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
,	NULL
lanes	NULL
4-6	NULL
)	NULL
and	NULL
unlabeled	NULL
«	NULL
B-like	NULL
site	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
A-C	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
,	NULL
indicating	NULL
the	NULL
specific	NULL
binding	NULL
of	NULL
complex	NULL
A-C.	NULL
From	NULL
activated	NULL
cells	NULL
with	NULL
PMA/ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EGTA	NULL
,	NULL
complex	NULL
C	NULL
was	NULL
detected	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
,	NULL
show	NULL
8586	NULL
IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
kB-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
55:1	NULL
gCompetilor	NULL
B	NULL
PMA+lonomycin	NULL
+FK506	NULL
c-Jun	NULL
JunB	NULL
JunD	NULL
c-Fos	NULL
I~	NULL
PMA+lonomycin	NULL
71	NULL
T	NULL
Antibody	NULL
:	NULL
-	NULL
c-Jun	NULL
JunB	NULL
JunD	NULL
c-Fos	NULL
PMA+lonomycin	NULL
supershifted	NULL
-	NULL
<	NULL
-	NULL
.	NULL

__	NULL
.	NULL

_4	NULL
AP-1	NULL
site	NULL
*	NULL
Y	NULL
AP-1	NULL
site	NULL
complex	NULL
complex	NULL
10	NULL
2	NULL
8	NULL
4	NULL
50	NULL
6	NULL
7	NULL
8	NULL
g	NULL
10	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

A	NULL
,	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
binding	NULL
complex	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
(	NULL
Zanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
5	NULL
)	NULL
,	NULL
and	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
ni	NULL
)	NULL
,	NULL
and	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
(	NULL
Zane	NULL
3	NULL
)	NULL
for	NULL
1	NULL
h	NULL
were	NULL
mixed	NULL
with	NULL
the	NULL
labeled	NULL
IL-8	NULL
promoter	NULL
(	NULL
-130	NULL
bp	NULL
to	NULL
-116	NULL
bp	NULL
)	NULL
,	NULL
containing	NULL
AP-1	NULL
site	NULL
(	NULL
-126	NULL
bp	NULL
to	NULL
-120	NULL
bp	NULL
;	NULL
TGACTCA	NULL
)	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
50	NULL
ng	NULL
of	NULL
AP-1	NULL
site	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
mutated	NULL
AP-1	NULL
site	NULL
competitors	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

B	NULL
,	NULL
the	NULL
IL-8	NULL
AP-1	NULL
binding	NULL
complex	NULL
was	NULL
recognized	NULL
by	NULL
anti-JunD	NULL
or	NULL
c-Fos	NULL
antibodies	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
ni	NULL
)	NULL
(	NULL
Zanes	NULL
1-5	NULL
)	NULL
or	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
FK506	NULL
(	NULL
10	NULL
ni	NULL
)	NULL
(	NULL
lanes	NULL
6-10	NULL
)	NULL
were	NULL
preincubated	NULL
without	NULL
(	NULL
lanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
or	NULL
with	NULL
antibodies	NULL
for	NULL
c-Jun	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
,	NULL
JunB	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
,	NULL
JunD	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
or	NULL
c-Fos	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
before	NULL
adding	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
probe	NULL
to	NULL
the	NULL
binding	NULL
mixtures	NULL
.	NULL

A	NULL
FK506	NULL
#	NULL
=	NULL
+	NULL
=	NULL
-	NULL
+	NULL
PMA+lonomycin	NULL
_	NULL
-	NULL
+	NULL
+	NULL
=	NULL
a	NULL
+	NULL
A	NULL
Complex	NULL
\	NULL
‘	NULL
B.	NULL
a	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
L	NULL
wild	NULL
type	NULL
-I	NULL
L	NULL
mutated	NULL
-J	NULL
probe	NULL
:	NULL
IL-8	NULL
xB-like	NULL
site	NULL
C	NULL
FKSO	NULL
‘	NULL
G	NULL
~	NULL
+	NULL
r	NULL
PMA+lonomycin	NULL
:	NULL
PMA+lonomycin	NULL
+	NULL
+	NULL
-	NULL
FK506	NULL
EGTA	NULL
A	NULL
4	NULL
B	NULL
»	NULL
1	NULL
2	NULL
1	NULL
2	NULL
3	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
.	NULL

A	NULL
,	NULL
three	NULL
complexes	NULL
were	NULL
formed	NULL
with	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

After	NULL
Jurkat	NULL
cells	NULL
were	NULL
untreated	NULL
(	NULL
Zanes	NULL
I	NULL
and	NULL
4	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
10	NULL
ng/ml	NULL
PMA	NULL
and	NULL
500	NULL
ny	NULL
ionomycin	NULL
(	NULL
Zanes	NULL
2	NULL
and	NULL
5	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
10	NULL
ng/ml	NULL
PMA	NULL
,	NULL
500	NULL
nM	NULL
ionomycin	NULL
,	NULL
and	NULL
10	NULL
nm	NULL
FK506	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
6	NULL
)	NULL
for	NULL
1	NULL
h	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
.	NULL

The	NULL
nuclear	NULL
extracts	NULL
were	NULL
mixed	NULL
with	NULL
labeled	NULL
oligonucleotide	NULL
of	NULL
IL-8	NULL
promoter	NULL
(	NULL
-83	NULL
bp	NULL
to	NULL
-69	NULL
bp	NULL
)	NULL
,	NULL
containing	NULL
the	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
-80	NULL
bp	NULL
to	NULL
-71	NULL
bp	NULL
;	NULL
GGAATTTCCT	NULL
)	NULL
(	NULL
Zanes	NULL
1-3	NULL
)	NULL
or	NULL
the	NULL
mutated	NULL
«	NULL
B-like	NULL
site	NULL
(	NULL
TAACTTTCCT	NULL
)	NULL
(	NULL
lanes	NULL
4-6	NULL
)	NULL
.	NULL

B	NULL
,	NULL
complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
showed	NULL
different	NULL
mobility	NULL
.	NULL

After	NULL
incubation	NULL
of	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
probe	NULL
and	NULL
nuclear	NULL
extracts	NULL
from	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
n	NULL
)	NULL
,	NULL
plus	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
the	NULL
mixture	NULL
were	NULL
run	NULL
on	NULL
polyacrylamide	NULL
gel	NULL
for	NULL
longer	NULL
time	NULL
(	NULL
4	NULL
h	NULL
)	NULL
.	NULL

C	NULL
,	NULL
calcium	NULL
chelator	NULL
(	NULL
EGTA	NULL
)	NULL
and	NULL
FK506	NULL
had	NULL
similar	NULL
effects	NULL
on	NULL
the	NULL
B-like	NULL
site	NULL
binding	NULL
complexes	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
;	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
EGTA	NULL
(	NULL
3	NULL
mi	NULL
;	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

ing	NULL
that	NULL
Ca*+*	NULL
chelator	NULL
mimicked	NULL
the	NULL
effects	NULL
of	NULL
FK506	NULL
on	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
binding	NULL
complexes	NULL
.	NULL

This	NULL
finding	NULL
suggested	NULL
that	NULL
Ca*+-dependent	NULL
pathway	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
complex	NULL
formation	NULL
of	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
,	NULL
which	NULL
is	NULL
affected	NULL
by	NULL
FK506	NULL
.	NULL

Antibodies	NULL
for	NULL
the	NULL
Rel	NULL
Family	NULL
Proteins	NULL
Did	NULL
Not	NULL
Recognize	NULL
Complexes	NULL
A-C-Since	NULL
the	NULL
Rel	NULL
family	NULL
proteins	NULL
can	NULL
bind	NULL
to	NULL
kB	NULL
sites	NULL
(	NULL
36	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
complexes	NULL
A-C	NULL
contain	NULL
the	NULL
Rel	NULL
family	NULL
proteins	NULL
such	NULL
as	NULL
c-Rel	NULL
,	NULL
p65	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p49	NULL
by	NULL
using	NULL
antibodies	NULL
against	NULL
these	NULL
proteins	NULL
.	NULL

None	NULL
of	NULL
the	NULL
complex	NULL
formations	NULL
were	NULL
affected	NULL
by	NULL
these	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
lanes	NULL
1-10	NULL
)	NULL
.	NULL

Under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
the	NULL
mobility	NULL
of	NULL
complex	NULL
between	NULL
NF-kB	NULL
and	NULL
the	NULL
«	NULL
B	NULL
site	NULL
of	NULL
Ig	NULL
k	NULL
chain	NULL
gene	NULL
was	NULL
decreased	NULL
by	NULL
either	NULL
anti-p65	NULL
or	NULL
p50	NULL
antibodies	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

The	NULL
anti-c-Rel	NULL
antibody	NULL
interfered	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
recombinant	NULL
c-Rel	NULL
to	NULL
an	NULL
intronic	NULL
enhancer	NULL
element	NULL
of	NULL
the	NULL
interferon-y	NULL
gene	NULL
(	NULL
37	NULL
)	NULL
and	NULL
supershifted	NULL
the	NULL
complex	NULL
between	NULL
c-Rel	NULL
in	NULL
PMA-stimulated	NULL
Jurkat	NULL
cells	NULL
and	NULL
the	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
receptor	NULL
«	NULL
chain	NULL
gene	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
kB	NULL
site	NULL
of	NULL
the	NULL
IL-6	NULL
gene	NULL
in	NULL
a	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
Daudi	NULL
,	NULL
were	NULL
supershifted	NULL
by	NULL
anti-c-Rel	NULL
,	NULL
p65	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p49	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
nuclear	NULL
factors	NULL
forming	NULL
complexes	NULL
A-C	NULL
in	NULL
Jurkat	NULL
cells	NULL
are	NULL
immuno-chemically	NULL
unrelated	NULL
to	NULL
c-Rel	NULL
,	NULL
p65	NULL
,	NULL
p50	NULL
,	NULL
and	NULL
p49	NULL
.	NULL

It	NULL
is	NULL
demonstrated	NULL
that	NULL
mitogenic	NULL
treatment	NULL
of	NULL
cells	NULL
strongly	NULL
induces	NULL
NF-kB	NULL
binding	NULL
activity	NULL
(	NULL
39	NULL
)	NULL
.	NULL

PMA/ionomycin	NULL
treatment	NULL
induced	NULL
the	NULL
transcriptional	NULL
activity	NULL
through	NULL
authentic	NULL
kB	NULL
site	NULL
of	NULL
the	NULL
Ig	NULL
gene	NULL
(	NULL
Fig	NULL
.	NULL

10A	NULL
)	NULL
.	NULL

FK506	NULL
decreased	NULL
this	NULL
transcriptional	NULL
activity	NULL
by	NULL
PMA/ionomycin	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
that	NULL
PMA/	NULL
ionomycin	NULL
treatment	NULL
strongly	NULL
induced	NULL
one	NULL
complex	NULL
bound	NULL
to	NULL
the	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
,	NULL
lanes	NULL
1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

FK506	NULL
treatment	NULL
decreased	NULL
the	NULL
amount	NULL
of	NULL
complex	NULL
formation	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

The	NULL
in	NULL
IL-8	NULL
AP-1	NULL
and	NULL
kB-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
8587	NULL
(	NULL
A	NULL
)	NULL
(	NULL
B	NULL
)	NULL
(	NULL
C	NULL
)	NULL
100	NULL
0	NULL
6	NULL
a	NULL
100	NULL
180	NULL
xB-like	NULL
site	NULL
°	NULL
so	NULL
é	NULL
-o-	NULL
g	NULL
T	NULL
m	NULL
é	NULL
)	NULL
&	NULL
**	NULL
xB	NULL
site	NULL
x	NULL
6	NULL
9	NULL
x	NULL
@	NULL
@	NULL
60	NULL
&	NULL
so	NULL
S	NULL
2	NULL
€	NULL
§	NULL
``	NULL
g	NULL
«	NULL
9	NULL
so	NULL
20	NULL
\O	NULL
20	NULL
\O	NULL
20	NULL
0	NULL
4	NULL
T	NULL
--	NULL
1	NULL
0	NULL
-	NULL
i	NULL
.\	NULL
?	NULL

0	NULL
-	NULL
-	NULL
T	NULL
a	NULL
1	NULL
hi	NULL
10	NULL
20	NULL
0	NULL
10	NULL
20	NULL
o	NULL
10	NULL
20	NULL
competitor	NULL
(	NULL
ng	NULL
)	NULL
competitor	NULL
(	NULL
ng	NULL
)	NULL
competitor	NULL
(	NULL
ng	NULL
)	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

The	NULL
authentic	NULL
«	NULL
B	NULL
site	NULL
of	NULL
Ig	NULL
x	NULL
chain	NULL
gene	NULL
and	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
similarly	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
A-C	NULL
.	NULL

Various	NULL
amounts	NULL
of	NULL
the	NULL
oligonucleotides	NULL
of	NULL
the	NULL
kB	NULL
site	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
of	NULL
the	NULL
Ig	NULL
k	NULL
chain	NULL
gene	NULL
(	NULL
open	NULL
circles	NULL
)	NULL
or	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
(	NULL
GGAATTTCCT	NULL
)	NULL
(	NULL
closed	NULL
circles	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
the	NULL
nuclear	NULL
extract	NULL
from	NULL
PMA/ionomycin-treated	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
PMA/ionomycin/FK506-treated	NULL
(	NULL
C	NULL
)	NULL
cells	NULL
prior	NULL
to	NULL
the	NULL
IL-8	NULL
B-like	NULL
site	NULL
probe	NULL
addition	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
complexes	NULL
A-C	NULL
were	NULL
quantified	NULL
by	NULL
a	NULL
bioimaging	NULL
analyzer	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
complex	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
competitor	NULL
is	NULL
assigned	NULL
as	NULL
a	NULL
value	NULL
of	NULL
100	NULL
.	NULL

PMA+ionomycin	NULL
+FK506	NULL
-	NULL
c-rel	NULL
pBS	NULL
p50	NULL
p49	NULL
PMA+ionomycin	NULL
Antibody	NULL
:	NULL
c-rel	NULL
p65	NULL
p50	NULL
p49	NULL
A	NULL
°	NULL
Complex	NULL
g	NULL
.	NULL

n	NULL
va	NULL
m	NULL
»	NULL
i	NULL
a	NULL
a	NULL
#	NULL
a*	NULL
ao	NULL
®	NULL
Complex	NULL
C	NULL
1°	NULL
20	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8s	NULL
9	NULL
10	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Complexes	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
did	NULL
not	NULL
react	NULL
with	NULL
antibodies	NULL
to	NULL
the	NULL
human	NULL
Rel	NULL
family	NULL
proteins	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
(	NULL
Zanes	NULL
1-5	NULL
)	NULL
or	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
,	NULL
plus	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
(	NULL
Zanes	NULL
6-10	NULL
)	NULL
were	NULL
preincubated	NULL
without	NULL
antibody	NULL
(	NULL
Zanes	NULL
1	NULL
and	NULL
6	NULL
)	NULL
or	NULL
with	NULL
antibodies	NULL
against	NULL
c-Rel	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
7	NULL
)	NULL
,	NULL
p65	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
8	NULL
)	NULL
,	NULL
p50	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
,	NULL
or	NULL
p49	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
10	NULL
)	NULL
.	NULL

Then	NULL
,	NULL
the	NULL
probe	NULL
of	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
was	NULL
added	NULL
.	NULL

duced	NULL
major	NULL
complex	NULL
was	NULL
supershifted	NULL
by	NULL
either	NULL
anti-p65	NULL
or	NULL
p50	NULL
antibody	NULL
(	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
PMA¥/ionomycin	NULL
induced	NULL
NF-kB	NULL
(	NULL
p65/p50	NULL
)	NULL
,	NULL
whose	NULL
induction	NULL
was	NULL
decreased	NULL
by	NULL
FK506	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
NF-kB	NULL
,	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
probe	NULL
detected	NULL
several	NULL
minor	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

10B	NULL
)	NULL
.	NULL

Since	NULL
oligomer	NULL
of	NULL
the	NULL
«	NULL
B	NULL
site	NULL
of	NULL
Ig	NULL
k	NULL
chain	NULL
gene	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
complexes	NULL
A-C	NULL
in	NULL
a	NULL
way	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
,	NULL
some	NULL
of	NULL
minor	NULL
complexes	NULL
detected	NULL
with	NULL
Ig	NULL
kB	NULL
site	NULL
probe	NULL
may	NULL
correspond	NULL
to	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
binding	NULL
complexes	NULL
A-C	NULL
.	NULL

These	NULL
observations	NULL
indicated	NULL
that	NULL
the	NULL
main	NULL
constituents	NULL
of	NULL
complexes	NULL
bound	NULL
to	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
were	NULL
different	NULL
from	NULL
those	NULL
bound	NULL
to	NULL
the	NULL
authentic	NULL
«	NULL
B	NULL
site	NULL
of	NULL
Ig	NULL
k	NULL
chain	NULL
gene	NULL
.	NULL

DISCUSSION	NULL
IL-8	NULL
has	NULL
potent	NULL
chemotactic	NULL
activity	NULL
for	NULL
T	NULL
lymphocytes	NULL
,	NULL
as	NULL
well	NULL
as	NULL
neutrophils	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
produced	NULL
IL-8	NULL
after	NULL
activation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
although	NULL
the	NULL
amount	NULL
(	NULL
60	NULL
pg/ml	NULL
)	NULL
of	NULL
produced	NULL
IL-8	NULL
was	NULL
relatively	NULL
low	NULL
.	NULL

Since	NULL
T	NULL
lymphocytes	NULL
are	NULL
10-fold	NULL
more	NULL
sensitive	NULL
to	NULL
IL-8	NULL
than	NULL
neutrophils	NULL
in	NULL
chemo-taxis	NULL
(	NULL
40	NULL
)	NULL
,	NULL
even	NULL
a	NULL
small	NULL
amount	NULL
of	NULL
IL-8	NULL
produced	NULL
by	NULL
T	NULL
lymphocytes	NULL
may	NULL
recruit	NULL
other	NULL
T	NULL
lymphocytes	NULL
rather	NULL
than	NULL
neutrophils	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
preferential	NULL
infiltration	NULL
of	NULL
T	NULL
lymphocytes	NULL
observed	NULL
at	NULL
inflammatory	NULL
sites	NULL
,	NULL
e.g	NULL
.	NULL

the	NULL
acute	NULL
phase	NULL
of	NULL
graft	NULL
rejection	NULL
(	NULL
41	NULL
)	NULL
,	NULL
delayed	NULL
type	NULL
hypersensitivity	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
reported	NULL
that	NULL
FK506	NULL
inhibits	NULL
the	NULL
infiltration	NULL
of	NULL
T	NULL
lymphocytes	NULL
into	NULL
the	NULL
allograft	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Since	NULL
FK506	NULL
suppressed	NULL
the	NULL
IL-8	NULL
production	NULL
by	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
tempting	NULL
to	NULL
speculate	NULL
that	NULL
FK506	NULL
may	NULL
inhibit	NULL
the	NULL
recruitment	NULL
of	NULL
T	NULL
lymphocytes	NULL
into	NULL
the	NULL
sites	NULL
of	NULL
acute	NULL
phase	NULL
graft	NULL
rejection	NULL
or	NULL
delayed	NULL
type	NULL
hypersensitivity	NULL
through	NULL
suppressing	NULL
the	NULL
IL-8	NULL
production	NULL
from	NULL
T	NULL
lymphocytes	NULL
that	NULL
have	NULL
migrated	NULL
,	NULL
thereby	NULL
inhibiting	NULL
immune	NULL
reactions	NULL
associated	NULL
with	NULL
T	NULL
cell	NULL
activities	NULL
at	NULL
such	NULL
sites	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
is	NULL
sensitive	NULL
to	NULL
FK506	NULL
upon	NULL
stimulation	NULL
of	NULL
PMA	NULL
and	NULL
Ca*+*-mobilizing	NULL
agents	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
previous	NULL
reports	NULL
describing	NULL
AP-1	NULL
sites	NULL
as	NULL
rather	NULL
resistant	NULL
to	NULL
the	NULL
immunosuppressants	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
14	NULL
)	NULL
.	NULL

These	NULL
contradictory	NULL
results	NULL
might	NULL
arise	NULL
from	NULL
several	NULL
differences	NULL
of	NULL
assay	NULL
system	NULL
between	NULL
our	NULL
report	NULL
and	NULL
other	NULL
reports	NULL
.	NULL

First	NULL
,	NULL
other	NULL
groups	NULL
used	NULL
the	NULL
SV40	NULL
large	NULL
T	NULL
antigen	NULL
expressing	NULL
Jurkat	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
or	NULL
murine	NULL
T	NULL
lymphoma	NULL
El4	NULL
cells	NULL
(	NULL
20	NULL
,	NULL
24	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
as	NULL
a	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
reporter	NULL
construction	NULL
of	NULL
AP-1	NULL
site-dependent	NULL
transcription	NULL
,	NULL
we	NULL
used	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
whose	NULL
activation	NULL
was	NULL
inhibited	NULL
by	NULL
FK506	NULL
,	NULL
while	NULL
others	NULL
used	NULL
the	NULL
AP-1	NULL
sites	NULL
of	NULL
the	NULL
metallothionein	NULL
gene	NULL
(	NULL
19	NULL
,	NULL
23	NULL
,	NULL
27	NULL
)	NULL
or	NULL
the	NULL
collagenase	NULL
gene	NULL
(	NULL
20	NULL
,	NULL
24	NULL
,	NULL
26	NULL
)	NULL
,	NULL
on	NULL
which	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
is	NULL
not	NULL
known	NULL
.	NULL

Moreover	NULL
,	NULL
TGACTCA	NULL
was	NULL
used	NULL
as	NULL
AP-1	NULL
binding	NULL
site	NULL
in	NULL
this	NULL
study	NULL
,	NULL
although	NULL
the	NULL
sequences	NULL
used	NULL
by	NULL
other	NULL
groups	NULL
(	NULL
GTGACTCAGCGCG	NULL
,	NULL
TCGAGTGACTCAGCGCGTCGA	NULL
,	NULL
and	NULL
GATGACTCAGCC	NULL
;	NULL
underline	NULL
indicates	NULL
AP-1	NULL
site	NULL
)	NULL
(	NULL
19	NULL
,	NULL
20	NULL
,	NULL
23	NULL
,	NULL
24	NULL
,	NULL
26	NULL
,	NULL
27	NULL
)	NULL
contained	NULL
extra	NULL
sequences	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
system	NULL
may	NULL
reflect	NULL
more	NULL
precise	NULL
AP-1	NULL
activity	NULL
.	NULL

In	NULL
gel	NULL
retardation	NULL
analysis	NULL
,	NULL
PMA/ionomycin	NULL
treatment	NULL
induced	NULL
the	NULL
IL-8	NULL
AP-1	NULL
binding	NULL
site	NULL
complex	NULL
containing	NULL
JunD	NULL
and	NULL
c-Fos	NULL
.	NULL

Although	NULL
FK506	NULL
apparently	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
induction	NULL
of	NULL
JunD/c-Fos	NULL
on	NULL
gel	NULL
retardation	NULL
analysis	NULL
,	NULL
the	NULL
PMA/ionomycin-induced	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
site	NULL
was	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
JunD/c-Fos	NULL
activating	NULL
mechanism	NULL
involving	NULL
Ca**	NULL
mobilization	NULL
,	NULL
which	NULL
is	NULL
sensitive	NULL
to	NULL
FK506	NULL
.	NULL

Recently	NULL
,	NULL
a	NULL
FK506-	NULL
and	NULL
cyclosporin	NULL
A-sensitive	NULL
factor	NULL
,	NULL
NFIL-2A	NULL
,	NULL
was	NULL
reported	NULL
to	NULL
contain	NULL
c-Jun	NULL
or	NULL
JunD	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
which	NULL
was	NULL
controlled	NULL
by	NULL
a	NULL
cyclosporin	NULL
A-sensitive	NULL
and	NULL
Ca*+-dependent	NULL
mechanism	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-8	NULL
AP-1	NULL
binding	NULL
complex	NULL
(	NULL
JunD/c-Fos	NULL
)	NULL
may	NULL
be	NULL
suppressed	NULL
by	NULL
FK506	NULL
in	NULL
such	NULL
manners	NULL
as	NULL
NFIL-2A	NULL
.	NULL

Although	NULL
the	NULL
suppressive	NULL
mechanisms	NULL
of	NULL
activity	NULL
of	NULL
Jun	NULL
proteins	NULL
by	NULL
immunosuppressive	NULL
drugs	NULL
remain	NULL
to	NULL
be	NULL
elucidated	NULL
at	NULL
present	NULL
,	NULL
it	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
families	NULL
is	NULL
regulated	NULL
by	NULL
phosphorylation	NULL
(	NULL
44	NULL
)	NULL
.	NULL

Several	NULL
serine	NULL
(	NULL
s	NULL
)	NULL
or	NULL
threonine	NULL
(	NULL
s	NULL
)	NULL
within	NULL
the	NULL
regulatory	NULL
region	NULL
of	NULL
c-Jun	NULL
,	NULL
c-Fos	NULL
are	NULL
phosphorylated	NULL
by	NULL
protein	NULL
kinase	NULL
A	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
casein	NULL
kinase	NULL
II	NULL
,	NULL
p34°	NULL
``	NULL
``	NULL
,	NULL
MAP	NULL
kinase	NULL
,	NULL
or	NULL
glycogen	NULL
synthase	NULL
kinase	NULL
3	NULL
(	NULL
45-47	NULL
)	NULL
.	NULL

Since	NULL
FK506	NULL
inhibits	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
(	NULL
48	NULL
)	NULL
,	NULL
the	NULL
phosphorylation	NULL
states	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
proteins	NULL
may	NULL
be	NULL
changed	NULL
by	NULL
FK506	NULL
treatment	NULL
in	NULL
Ca*+*+-dependent	NULL
manner	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
suppression	NULL
of	NULL
transcriptional	NULL
activity	NULL
of	NULL
Jun	NULL
and	NULL
Fos	NULL
proteins	NULL
with	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
binding	NULL
activity	NULL
.	NULL

The	NULL
factors	NULL
forming	NULL
complexes	NULL
A-C	NULL
with	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
8588	NULL
ER	NULL
control	NULL
C	NULL
PMA+lonomycin	NULL
60000	NULL
EJ	NULL
]	NULL
PMA+lonomycin+FK506	NULL
3	NULL
7	NULL
50000	NULL
[	NULL
est	NULL
>	NULL
40000	NULL
£	NULL
<	NULL
30000	NULL
fol	NULL
€	NULL
3	NULL
20000	NULL
7	NULL
's	NULL
m	NULL
43	NULL
10000	NULL
o	NULL
4	NULL
X2	NULL
1g	NULL
xB	NULL
site	NULL
LUC	NULL
IL-8	NULL
AP-1	NULL
and	NULL
kB-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
p6S5	NULL
p50	NULL
-	NULL
p49	NULL
Antibody	NULL
~	NULL
~	NULL
+	NULL
-	NULL
=	NULL
-	NULL
-	NULL
FK506	NULL
~	NULL
+o	NULL
o	NULL
+	NULL
o	NULL
+	NULL
o	NULL
+	NULL
0	NULL
+	NULL
=_	NULL
+	NULL
PMA+lonomycin	NULL
H	NULL
i	NULL
C	NULL
_	NULL
H	NULL
“	NULL
fNF-KB	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
_	NULL
7	NULL
Fic	NULL
.	NULL

10	NULL
.	NULL

A	NULL
,	NULL
FK506	NULL
suppressed	NULL
the	NULL
PMA/ionomycin-induced	NULL
transcription	NULL
through	NULL
authentic	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
Ig	NULL
gene	NULL
.	NULL

Two	NULL
copies	NULL
of	NULL
Ig	NULL
kB	NULL
site	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
upstream	NULL
of	NULL
the	NULL
IL-8	NULL
enhancerless	NULL
promoter	NULL
linked	NULL
to	NULL
luciferase	NULL
gene	NULL
.	NULL

The	NULL
transfected	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/m1	NULL
)	NULL
,	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
for	NULL
8	NULL
h	NULL
before	NULL
the	NULL
luciferase	NULL
assay	NULL
.	NULL

R.L.U	NULL
.	NULL

,	NULL
relative	NULL
light	NULL
unit	NULL
.	NULL

B	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
strongly	NULL
induced	NULL
NF-kB	NULL
,	NULL
which	NULL
was	NULL
decreased	NULL
by	NULL
FK506	NULL
treatment	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
unstimulated	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
,	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
500	NULL
nm	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4-7	NULL
)	NULL
or	NULL
presence	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
of	NULL
FK506	NULL
(	NULL
10	NULL
nm	NULL
)	NULL
were	NULL
incubated	NULL
without	NULL
(	NULL
lanes	NULL
1-3	NULL
)	NULL
or	NULL
with	NULL
antibodies	NULL
against	NULL
c-Rel	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
p65	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
p50	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
or	NULL
p49	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
authentic	NULL
kB	NULL
site	NULL
probe	NULL
(	NULL
GGGACTTTCC	NULL
)	NULL
of	NULL
Ig	NULL
x	NULL
chain	NULL
gene	NULL
.	NULL

are	NULL
distinct	NULL
from	NULL
the	NULL
reported	NULL
Rel	NULL
family	NULL
proteins	NULL
in	NULL
several	NULL
terms	NULL
.	NULL

First	NULL
,	NULL
the	NULL
pattern	NULL
of	NULL
complexes	NULL
detected	NULL
by	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
was	NULL
different	NULL
from	NULL
that	NULL
by	NULL
the	NULL
authentic	NULL
Ig	NULL
x	NULL
site	NULL
,	NULL
to	NULL
which	NULL
NF-kB	NULL
(	NULL
p65/p50	NULL
)	NULL
bound	NULL
.	NULL

Second	NULL
,	NULL
antibodies	NULL
specific	NULL
for	NULL
Rel	NULL
family	NULL
proteins	NULL
failed	NULL
to	NULL
recognize	NULL
complexes	NULL
A-C.	NULL
Third	NULL
,	NULL
upon	NULL
partial	NULL
purification	NULL
with	NULL
heparin-high	NULL
performance	NULL
liquid	NULL
chromatography	NULL
,	NULL
complexes	NULL
A-C	NULL
were	NULL
eluted	NULL
at	NULL
a	NULL
different	NULL
point	NULL
from	NULL
that	NULL
of	NULL
NF-kB	NULL
(	NULL
p65/p50	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
consensus	NULL
sequence	NULL
bound	NULL
by	NULL
NF-kB	NULL
is	NULL
GGGRNNYYCC	NULL
(	NULL
R	NULL
,	NULL
purines	NULL
;	NULL
Y	NULL
,	NULL
pyrimidines	NULL
;	NULL
N	NULL
,	NULL
any	NULL
nucleotides	NULL
)	NULL
(	NULL
39	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
IL-8	NULL
«	NULL
B-like	NULL
site	NULL
is	NULL
TGGAATTTCC	NULL
(	NULL
-81	NULL
bp	NULL
to	NULL
-72	NULL
bp	NULL
)	NULL
,	NULL
or	NULL
AG-GAAATTCC	NULL
(	NULL
-80	NULL
bp	NULL
to	NULL
-71	NULL
bp	NULL
in	NULL
the	NULL
reverse	NULL
orientation	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
does	NULL
not	NULL
completely	NULL
fit	NULL
for	NULL
the	NULL
consensus	NULL
sequence	NULL
of	NULL
kB	NULL
sites	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
the	NULL
slight	NULL
difference	NULL
of	NULL
the	NULL
IL-8	NULL
kB-like	NULL
site	NULL
from	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
sites	NULL
may	NULL
cause	NULL
the	NULL
difference	NULL
of	NULL
the	NULL
nuclear	NULL
factors	NULL
mainly	NULL
bound	NULL
to	NULL
the	NULL
IL-8	NULL
«	NULL
kB-like	NULL
site	NULL
from	NULL
those	NULL
to	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
sites	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
kB	NULL
sites	NULL
to	NULL
immunosuppressive	NULL
drugs	NULL
is	NULL
in	NULL
controversy	NULL
(	NULL
14	NULL
,	NULL
20	NULL
,	NULL
21	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

We	NULL
confirmed	NULL
the	NULL
previous	NULL
finding	NULL
that	NULL
FK506	NULL
suppresses	NULL
Ca*+-dependent	NULL
transcriptional	NULL
activation	NULL
through	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
,	NULL
which	NULL
is	NULL
correlated	NULL
with	NULL
the	NULL
change	NULL
in	NULL
NF-kB	NULL
binding	NULL
activity	NULL
to	NULL
the	NULL
Ig	NULL
«	NULL
B	NULL
site	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
newly	NULL
identified	NULL
the	NULL
IL-8	NULL
«	NULL
kB-like	NULL
site	NULL
,	NULL
to	NULL
which	NULL
NF-kB	NULL
binding	NULL
was	NULL
not	NULL
observed	NULL
,	NULL
as	NULL
an	NULL
FK506-sensitive	NULL
site	NULL
.	NULL

These	NULL
findings	NULL
suggest	NULL
that	NULL
the	NULL
extent	NULL
of	NULL
FK506	NULL
action	NULL
is	NULL
not	NULL
NF-	NULL
«	NULL
B-restricted	NULL
,	NULL
but	NULL
expands	NULL
to	NULL
other	NULL
«	NULL
B	NULL
(	NULL
-like	NULL
)	NULL
site	NULL
binding	NULL
factors	NULL
.	NULL

Ca**	NULL
is	NULL
an	NULL
essential	NULL
signal	NULL
mediator	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
49	NULL
)	NULL
.	NULL

FK506	NULL
is	NULL
thought	NULL
to	NULL
block	NULL
the	NULL
signal	NULL
transduction	NULL
,	NULL
thereby	NULL
suppressing	NULL
T	NULL
cell	NULL
functions	NULL
such	NULL
as	NULL
cytokine	NULL
production	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
cytokines	NULL
,	NULL
of	NULL
which	NULL
production	NULL
is	NULL
suppressed	NULL
by	NULL
FK506	NULL
,	NULL
are	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-4	NULL
,	NULL
granulocyte	NULL
macrophage-colony	NULL
stimulating	NULL
factor	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
,	NULL
and	NULL
interferon-y	NULL
(	NULL
15-18	NULL
)	NULL
.	NULL

Among	NULL
them	NULL
,	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
targets	NULL
of	NULL
FK506-sensitive	NULL
and	NULL
Ca*+*-dependent	NULL
signal	NULL
pathway	NULL
(	NULL
14	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
IL-8	NULL
is	NULL
newly	NULL
added	NULL
to	NULL
the	NULL
member	NULL
of	NULL
cytokines	NULL
whose	NULL
production	NULL
is	NULL
suppressed	NULL
by	NULL
FK506	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
AP-1	NULL
and	NULL
«	NULL
kB-like	NULL
sites	NULL
of	NULL
the	NULL
IL-8	NULL
gene	NULL
are	NULL
also	NULL
targets	NULL
of	NULL
the	NULL
FK506-sensitive	NULL
pathway	NULL
accompanied	NULL
by	NULL
Ca**	NULL
mobili-zation	NULL
.	NULL

Our	NULL
findings	NULL
suggest	NULL
that	NULL
multiple	NULL
transcriptional	NULL
ele-ments	NULL
,	NULL
not	NULL
restricted	NULL
to	NULL
NF-AT	NULL
and	NULL
NFIL-2A	NULL
sites	NULL
,	NULL
of	NULL
cytokine	NULL
genes	NULL
may	NULL
be	NULL
controlled	NULL
by	NULL
Ca*+-dependent	NULL
FK506-sensitive	NULL
mechanisms	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Acknowledgments-We	NULL
are	NULL
very	NULL
grateful	NULL
to	NULL
Drs	NULL
.	NULL

K.	NULL
Kuno	NULL
,	NULL
H.	NULL
No-mura	NULL
,	NULL
and	NULL
A.	NULL
Harada	NULL
for	NULL
the	NULL
excellent	NULL
technical	NULL
advice	NULL
,	NULL
to	NULL
Dr.	NULL
B.	NULL
W.	NULL
Nielsen	NULL
for	NULL
reviewing	NULL
this	NULL
manuscript	NULL
,	NULL
and	NULL
to	NULL
Dr.	NULL
M.	NULL
Fujii	NULL
for	NULL
helpful	NULL
discussions	NULL
and	NULL
encouragement	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Matsushima	NULL
,	NULL
K.	NULL
,	NULL
Baldwin	NULL
,	NULL
E.	NULL
T.	NULL
,	NULL
and	NULL
Mukaida	NULL
,	NULL
N.	NULL
(	NULL
1992	NULL
)	NULL
Chem	NULL
.	NULL

Immunol	NULL
.	NULL

51	NULL
,	NULL
236-265	NULL
2	NULL
.	NULL

Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Harada	NULL
,	NULL
A.	NULL
,	NULL
Yasumoto	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
Microbiol	NULL
.	NULL

Immunol	NULL
.	NULL

36	NULL
,	NULL
773-789	NULL
3	NULL
.	NULL

Huber	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Todd	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
III	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
99-102	NULL
4	NULL
.	NULL

Jagels	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Hugli	NULL
,	NULL
T.	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1119-1128	NULL
5	NULL
.	NULL

Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Mahe	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
21128-21133	NULL
6	NULL
.	NULL

Mahé	NULL
,	NULL
Y.	NULL
,	NULL
Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Kuno	NULL
,	NULL
K.	NULL
,	NULL
Akiyama	NULL
,	NULL
M.	NULL
,	NULL
Ikeda	NULL
,	NULL
N.	NULL
,	NULL
Matsushima	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Murakami	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
13759-13763	NULL
7	NULL
.	NULL

Yasumoto	NULL
,	NULL
K.	NULL
,	NULL
Okamoto	NULL
,	NULL
S.-i	NULL
.	NULL

,	NULL
Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Murakami	NULL
,	NULL
S.	NULL
,	NULL
Mai	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267	NULL
,	NULL
22506-22511	NULL
8	NULL
.	NULL

Standiford	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Strieter	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Chensue	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
Westwick	NULL
,	NULL
J.	NULL
,	NULL
Kasahara	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

145	NULL
,	NULL
1435-1439	NULL
9	NULL
.	NULL

Malefyt	NULL
,	NULL
R.	NULL
d.	NULL
W.	NULL
,	NULL
Abrams	NULL
,	NULL
J.	NULL
,	NULL
Bennett	NULL
,	NULL
B.	NULL
,	NULL
Figdor	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
and	NULL
deVries	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

174	NULL
,	NULL
1209-1220	NULL
10	NULL
.	NULL

Oliveira	NULL
,	NULL
I.	NULL
C.	NULL
,	NULL
Sciavolino	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Lee	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
and	NULL
Viléek	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
9049-9053	NULL
11	NULL
.	NULL

Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Shiroo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
1366-1371	NULL
12	NULL
.	NULL

Larsen	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Kristensen	NULL
,	NULL
M.	NULL
,	NULL
Paludan	NULL
,	NULL
K.	NULL
,	NULL
Deleuran	NULL
,	NULL
B.	NULL
,	NULL
Thomsen	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Zachariae	NULL
,	NULL
C.	NULL
,	NULL
Kragballe	NULL
,	NULL
K.	NULL
,	NULL
Matsushima	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Thestrup-Pedersen	NULL
,	NULL
K.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

176	NULL
,	NULL
1020-1026	NULL
13	NULL
.	NULL

Zipfel	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
Bialonski	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Skerka	NULL
,	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

181	NULL
,	NULL
179-183	NULL
14	NULL
.	NULL

Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
136-142	NULL
15	NULL
.	NULL

Reem	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
Cook	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
and	NULL
Viléek	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Science	NULL
221	NULL
,	NULL
63-65	NULL
16	NULL
.	NULL

Elliott	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
Y.	NULL
,	NULL
Mizel	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Bleackley	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Harnish	NULL
,	NULL
D.	NULL
G.	NULL
,	NULL
and	NULL
Paetkau	NULL
,	NULL
V.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
226	NULL
,	NULL
1439-1441	NULL
17	NULL
.	NULL

Bickel	NULL
,	NULL
M.	NULL
,	NULL
Tsuda	NULL
,	NULL
H.	NULL
,	NULL
Amstad	NULL
,	NULL
P.	NULL
,	NULL
Evenquoz	NULL
,	NULL
V.	NULL
,	NULL
Mergenhagen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Wahl	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Pluznik	NULL
,	NULL
D.	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

84	NULL
,	NULL
3274-3277	NULL
Tocci	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Matkovich	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Collier	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Kwok	NULL
,	NULL
P.	NULL
,	NULL
Dumont	NULL
,	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
S.	NULL
,	NULL
Degudicibus	NULL
,	NULL
S.	NULL
,	NULL
Siekierka	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Chin	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Hutchinson	NULL
,	NULL
N.	NULL
I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

1483	NULL
,	NULL
718-726	NULL
19	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Verweij	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Higgins	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Lacy	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
1617-1620	NULL
Randak	NULL
,	NULL
C.	NULL
,	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Hergenrither	NULL
,	NULL
M.	NULL
,	NULL
Sobotta	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
2529-2536	NULL
18	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Hennighausen	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

64	NULL
,	NULL
4037-4041	NULL
22	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
P.	NULL
,	NULL
Inaba	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Steinman	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
1869-1872	NULL
23	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
McCutcheon	NULL
,	NULL
M.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

9	NULL
,	NULL
4425-4433	NULL
24	NULL
.	NULL

Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Pietrowski	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
61-67	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

IL-8	NULL
AP-1	NULL
and	NULL
«	NULL
B-like	NULL
Sites	NULL
Are	NULL
Targets	NULL
of	NULL
FK506	NULL
Action	NULL
Banerji	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Parsons	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
and	NULL
Tocei	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

11	NULL
,	NULL
4074-4087	NULL
Brabletz	NULL
,	NULL
T.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
Schorr	NULL
,	NULL
E.	NULL
,	NULL
Siebelt	NULL
,	NULL
F.	NULL
,	NULL
Wirth	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Serfling	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
1155-1162	NULL
Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
188-196	NULL
Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Raptis	NULL
,	NULL
A.	NULL
,	NULL
Ahuja	NULL
,	NULL
S.	NULL
S.	NULL
,	NULL
Najjar	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91	NULL
,	NULL
1481-1489	NULL
Ko	NULL
,	NULL
Y.	NULL
,	NULL
Mukaida	NULL
,	NULL
N.	NULL
,	NULL
Panyutich	NULL
,	NULL
A.	NULL
,	NULL
Voitenok	NULL
,	NULL
N.	NULL
N.	NULL
,	NULL
Matsushima	NULL
,	NULL
K.	NULL
,	NULL
Kawai	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Kasahara	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
149	NULL
,	NULL
227-235	NULL
Brownell	NULL
,	NULL
E.	NULL
,	NULL
Mitterender	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Oncogene	NULL
4	NULL
,	NULL
985-942	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
,	NULL
Copeland	NULL
,	NULL
T.	NULL
D.	NULL
,	NULL
Simek	NULL
,	NULL
S.	NULL
,	NULL
Oroszlan	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Gilden	NULL
,	NULL
R.	NULL
V.	NULL
(	NULL
1986	NULL
)	NULL
Virology	NULL
149	NULL
,	NULL
217-229	NULL
Higuchi	NULL
,	NULL
R.	NULL
,	NULL
Krummel	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Saiki	NULL
,	NULL
R.	NULL
K.	NULL
(	NULL
1988	NULL
)	NULL
Nucleic	NULL
Acids	NULL
.	NULL

Res	NULL
.	NULL

16	NULL
,	NULL
7351-7367	NULL
Fujita	NULL
,	NULL
T.	NULL
,	NULL
Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Ohashi	NULL
,	NULL
T.	NULL
,	NULL
Yamanishi	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
401-407	NULL
Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Moffat	NULL
,	NULL
L.	NULL
F.	NULL
,	NULL
and	NULL
Howard	NULL
,	NULL
B.	NULL
H.	NULL
(	NULL
1982	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2	NULL
,	NULL
1044-1051	NULL
Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Lebovitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
Bose	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Jr.	NULL
(	NULL
1992	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1114	NULL
,	NULL
1-17	NULL
37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

8589	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
,	NULL
Kretzschmar	NULL
,	NULL
M.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
1740-1744	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Huang	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
and	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4067-4075	NULL
Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
63-80	NULL
Larsen	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Anderson	NULL
,	NULL
A.	NULL
O.	NULL
,	NULL
Appella	NULL
,	NULL
E.	NULL
,	NULL
Oppenheim	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
and	NULL
Matsushima	NULL
,	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1464-1466	NULL
Hayry	NULL
,	NULL
P.	NULL
,	NULL
Leszezynski	NULL
,	NULL
D.	NULL
,	NULL
Nemlander	NULL
,	NULL
A.	NULL
,	NULL
Ferry	NULL
,	NULL
B.	NULL
,	NULL
Renkonen	NULL
,	NULL
R.	NULL
,	NULL
yon	NULL
Wil-lenbrand	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Halttunen	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Ann	NULL
,	NULL
N.	NULL
Y.	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

582	NULL
,	NULL
86-105	NULL
.	NULL

Gawkrodger	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
McVittie	NULL
,	NULL
E.	NULL
,	NULL
Carr	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
Ross	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Hunter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

66	NULL
,	NULL
590-598	NULL
.	NULL

Bishop	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
and	NULL
Li	NULL
,	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1049-1054	NULL
.	NULL

Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Smeal	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

17	NULL
,	NULL
418-422	NULL
.	NULL

Abate	NULL
,	NULL
C.	NULL
,	NULL
Marshak	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Curran	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
2179-2185	NULL
.	NULL

Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Defize	NULL
,	NULL
L.	NULL
H.	NULL
K.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
573-584	NULL
.	NULL

Baker	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Luk	NULL
,	NULL
D.	NULL
,	NULL
Vandenberg	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Marshak	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Abate	NULL
,	NULL
C.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4694-4705	NULL
.	NULL

Fruman	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Klee	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Bierer	NULL
,	NULL
B.	NULL
F.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
3686-3690	NULL
.	NULL

Gardner	NULL
,	NULL
P.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
15-20	NULL

